Virosomes as a carrier delivery system for mRNA or adeno virus vector based vaccine candidates

病毒体作为基于 mRNA 或腺病毒载体的候选疫苗的载体递送系统

• 批准号: 2588817
• 金额: --
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2588817
• 关键词: Virosomes; carrier; delivery; system; mRNA

mRNA based vaccines have proven successful in curbing the global COVID-19 pandemic particularly in higher income countries. Current vaccines are formulated in lipid nanoparticles but require a restrictive cold-chain (-15C to-60C) which may be not feasible commercially/ logistically when compared to other subunit vaccines approaches typically stored at 4-8 C. Virosomes are an alternative carrier system commercialised with good safety and efficacy data for Hepatitis A (Epaxal) and Influenza (Inflexal) vaccines.The aim of this project will be to evaluate the feasibility of incorporating candidate mRNA sequences of various sizes into virosomes through different methods including encapsulation, surface linkage and with linkers. The manufacturability, storage stability and infectivity of the virosomes will be evaluated to enable the engineering of an optimal design. This work will have a major impact on the ability to rapidly respond to emerging disease threats. Knowledge gained from this project will also develop valuable tools that may also be applied to other virosome-based therapies, such as gene therapies. This research aligns well the EPSRC Manufacturing the Future Theme, and also the Transforming Healthcare theme.

基于mRNA的疫苗已被证明成功遏制全球COVID-19大流行，尤其是在高收入国家。目前的疫苗采用脂质纳米颗粒配制，但需要限制性冷链（-15 ° C至-60 ° C），与通常储存在4-8 ° C的其他亚单位疫苗方法相比，这在商业/后勤上可能不可行。病毒体是一种替代性的载体系统，已商业化，用于甲型肝炎（Epaxal）和流感（Inflexal）疫苗，具有良好的安全性和有效性数据。本项目的目的是评估通过不同方法（包括包封、表面连接和连接）将不同大小的候选mRNA序列整合到病毒体中的可行性。将评价病毒体的可生产性、储存稳定性和感染性，以实现最佳设计的工程化。这项工作将对迅速应对新出现的疾病威胁的能力产生重大影响。从该项目中获得的知识也将开发出有价值的工具，这些工具也可能应用于其他基于病毒体的疗法，如基因疗法。这项研究很好地结合了EPSRC制造未来的主题，也是转变医疗保健的主题。